OncoMatch/Clinical Trials/NCT06122896
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Is NCT06122896 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Magnetic Resonance Imaging and Magnetic Resonance Cholangiopancreatography for pancreatic cancer.
Treatment: Magnetic Resonance Imaging · Magnetic Resonance Cholangiopancreatography — The purpose of this research is to see if adding blood-based tests and symptom review to standard-of-care pancreatic cancer screening procedures can identify cancer early among individuals with increased risk.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: ATM pathogenic/likely pathogenic germline variant
Required: BRCA1 pathogenic/likely pathogenic germline variant
Required: BRCA2 pathogenic/likely pathogenic germline variant
Required: CDKN2A pathogenic/likely pathogenic germline variant
Required: EPCAM pathogenic/likely pathogenic germline variant
Required: MLH1 pathogenic/likely pathogenic germline variant
Required: MSH2 pathogenic/likely pathogenic germline variant
Required: MSH6 pathogenic/likely pathogenic germline variant
Required: PALB2 pathogenic/likely pathogenic germline variant
Required: PRSS1 pathogenic/likely pathogenic variant
Required: STK11 pathogenic/likely pathogenic germline variant
Required: TP53 pathogenic/likely pathogenic germline variant
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify